Parkinson's Disease/Movement Disorders News

Annovis Bio announced it received a positive safety review from an independent Data and Safety Monitoring Board for its phase 3 trial of buntanetap, a drug for treatment of patients with early Parkinson’s disease.

The FDA has declined to approve Amneal Pharmaceuticals’ new drug application for IPX203, a novel, oral formulation of extended-release carbidopa/levodopa designed for the treatment of Parkinson’s disease.

A Seattle-based biotechnology company announced completion of a $52.9 million Series B financing round to advance clinical trials of novel therapeutics for Alzheimer’s and Parkinson’s diseases.

A Bay Area bioelectronic medicine company announced the commercial launch of its next-generation Cala kIQ System, an FDA-cleared wearable device to relieve hand tremors in people with essential tremor and Parkinson’s disease.

Treatment with valbenazine at doses up to 80 mg once daily was generally well-tolerated and significantly improved chorea compared with placebo in adults with Huntington’s disease, according to research in The Lancet Neurology.

CHICAGO — Preference for using a movement-prompting rehabilitation device was higher among adults with mild Parkinson’s disease, with safety concerns growing in those with more advanced disease, according to research.

WASHINGTON — Among patients with Parkinson’s disease, obstructive sleep apnea and decreased cognition, CPAP therapy improved cognitive function, according to an abstract presented at the American Thoracic Society International Conference.

CHICAGO — Adults with tardive dyskinesia prescribed deutetrabenazine had better adherence and were less likely to discontinue treatment compared with those on valbenazine, although the differences were not statistically significant.

CHICAGO — Use of an in-home therapy desk improved motor skills and balance and reduced sedentarism in adults with Parkinson’s disease, according to data at the International Association of Parkinsonism and Related Disorders World Congress.

CHICAGO — Deep brain stimulation was a cost-effective and clinically efficacious option for advanced Parkinson’s disease compared with medical therapy for patients in the Vietnamese health care system, according to research.